Pieter A Cohen1, John C Travis2, Peter H J Keizers3, Patricia Deuster4, Bastiaan J Venhuis5. 1. a Harvard Medical School, Cambridge Health Alliance , Cambridge , MA , USA. 2. b NSF International , Ann Arbor , MI , USA. 3. c National Institute for Public Health and the Environment (RIVM), Health Protection Center , Bilthoven , The Netherlands. 4. d United States Department of Defense , Consortium for Health and Military Performance, Uniformed Services University , Bethesda , MD , USA. 5. e National Institute for Public Health and the Environment (RIVM), Health Protection Center , Bilthoven , The Netherlands.
Abstract
BACKGROUND: The United States Food and Drug Administration banned the stimulant 1,3-dimethylamylamine (1,3-DMAA) from dietary supplements and warned consumers that the stimulant can pose cardiovascular risks ranging from high blood pressure to heart attacks. OBJECTIVES: We designed our study to determine if a new stimulant similar in structure to 1,3-DMAA has been introduced as an ingredient in supplements sold in the United States (US). METHODS: We analyzed six brands of supplements that listed an ingredient on the label (e.g., Aconitum kusnezoffii, DMHA or 2-amino-isoheptane) that might refer to an analog of 1,3-DMAA. Supplements were analyzed by two separate laboratories using ultra-high-performance liquid chromatography mass spectrometry and reference standards. RESULTS: Two previously unidentified 1,3-DMAA analogs (2-amino-6-methylheptane [octodrine] and 1,4-dimethylamylamine [1,4-DMAA]) and two banned stimulants (1,3-DMAA and 1,3-dimethylbutylamine [1,3-DMBA]) were identified. Octodrine was found at a dose (±95% CI) of 72 ± 7.5 mg per serving. In Europe, octodrine was previously sold as a pharmaceutical in multi-ingredient medications at dosages from 8 to 33 mg. The quantity of octodrine found in our study was more than twice the largest pharmaceutical dose. The other new stimulant, 1,4-DMAA, has not previously been approved for human consumption, and its safety in humans is unknown. 1,4-DMAA was found at dosages between 21 ± 11 mg to 94 ± 48 mg per serving. In addition, two banned stimulants - 1,3-DMAA and 1,3-DMBA - were also identified: 24 ± 7.6 mg to 35 ± 11 mg of 1,3-DMAA and 51 ± 16 mg of 1,3-DMBA. In one product, 24 ± 7.6 mg of 1,3-DMAA was combined with 21 ± 11 mg of 1,4-DMAA. 1,3-DMAA has been investigated as potentially contributing to hemorrhagic strokes and sudden death, whereas the safety of 1,3-DMBA in humans is unknown. CONCLUSION: Two banned stimulants (1,3-DMAA and 1,3-DMBA) and two previously unidentified stimulants (1,4-DMAA and octodrine) were identified in supplements sold in the United States.
BACKGROUND: The United States Food and Drug Administration banned the stimulant 1,3-dimethylamylamine (1,3-DMAA) from dietary supplements and warned consumers that the stimulant can pose cardiovascular risks ranging from high blood pressure to heart attacks. OBJECTIVES: We designed our study to determine if a new stimulant similar in structure to 1,3-DMAA has been introduced as an ingredient in supplements sold in the United States (US). METHODS: We analyzed six brands of supplements that listed an ingredient on the label (e.g., Aconitum kusnezoffii, DMHA or 2-amino-isoheptane) that might refer to an analog of 1,3-DMAA. Supplements were analyzed by two separate laboratories using ultra-high-performance liquid chromatography mass spectrometry and reference standards. RESULTS: Two previously unidentified 1,3-DMAA analogs (2-amino-6-methylheptane [octodrine] and 1,4-dimethylamylamine [1,4-DMAA]) and two banned stimulants (1,3-DMAA and 1,3-dimethylbutylamine [1,3-DMBA]) were identified. Octodrine was found at a dose (±95% CI) of 72 ± 7.5 mg per serving. In Europe, octodrine was previously sold as a pharmaceutical in multi-ingredient medications at dosages from 8 to 33 mg. The quantity of octodrine found in our study was more than twice the largest pharmaceutical dose. The other new stimulant, 1,4-DMAA, has not previously been approved for human consumption, and its safety in humans is unknown. 1,4-DMAA was found at dosages between 21 ± 11 mg to 94 ± 48 mg per serving. In addition, two banned stimulants - 1,3-DMAA and 1,3-DMBA - were also identified: 24 ± 7.6 mg to 35 ± 11 mg of 1,3-DMAA and 51 ± 16 mg of 1,3-DMBA. In one product, 24 ± 7.6 mg of 1,3-DMAA was combined with 21 ± 11 mg of 1,4-DMAA. 1,3-DMAA has been investigated as potentially contributing to hemorrhagic strokes and sudden death, whereas the safety of 1,3-DMBA in humans is unknown. CONCLUSION: Two banned stimulants (1,3-DMAA and 1,3-DMBA) and two previously unidentified stimulants (1,4-DMAA and octodrine) were identified in supplements sold in the United States.
Entities:
Keywords:
Cardiovascular; dietary supplements; weight loss supplements; sports supplements
Authors: Valeria Catalani; Mariya Prilutskaya; Ahmed Al-Imam; Shanna Marrinan; Yasmine Elgharably; Mire Zloh; Giovanni Martinotti; Robert Chilcott; Ornella Corazza Journal: Brain Sci Date: 2018-02-20
Authors: Alessandra Durazzo; Barbara C Sorkin; Massimo Lucarini; Pavel A Gusev; Adam J Kuszak; Cindy Crawford; Courtney Boyd; Patricia A Deuster; Leila G Saldanha; Bill J Gurley; Pamela R Pehrsson; James M Harnly; Aida Turrini; Karen W Andrews; Andrea T Lindsey; Michael Heinrich; Johanna T Dwyer Journal: Front Pharmacol Date: 2022-01-11 Impact factor: 5.810
Authors: Jason M Nagata; Vivienne M Hazzard; Kyle T Ganson; S Bryn Austin; Dianne Neumark-Sztainer; Marla E Eisenberg Journal: Prev Med Rep Date: 2022-03-22
Authors: Irum Shaheen; Khuram Shahzad Ahmad; Camila Zequine; Ram K Gupta; Andrew Thomas; Mohammad Azad Malik Journal: RSC Adv Date: 2020-02-25 Impact factor: 4.036
Authors: Patrick S Harty; Hannah A Zabriskie; Jacob L Erickson; Paul E Molling; Chad M Kerksick; Andrew R Jagim Journal: J Int Soc Sports Nutr Date: 2018-08-08 Impact factor: 5.150